This is read by an automated voice. Please report any issues or inconsistencies here. Scientists are trying a revolutionary new approach to treat rheumatoid arthritis, multiple sclerosis, lupus and ...

Fluor (FLR) just broke ground on the State Highway 6 expansion in Texas, a project that neatly illustrates how its infrastructure backlog and lower risk, reimbursable contracts are reshaping the ...

GLP-1 is the naturally produced hormone whose function is being mimicked by drugs like semaglutide and tirzepatide, the active ingredients in popular and highly effective weight-loss drugs like Wegovy ...

Fluor Corporation (NYSE:FLR) shares rose Friday after the company reported third-quarter 2025 results that beat profit expectations but missed on revenue. Adjusted earnings per share were 68 cents, ...

Metabolic reprogramming in fibrotic lung diseases involves key metabolites like lactate, succinate, and 2-hydroxyglutarate, driving inflammation and fibroblast activation. Lactate accumulation ...

The cost of sequencing DNA has dropped dramatically, and with technologies like CRISPR, gene editing is becoming more precise and powerful than ever. From curing genetic diseases to designing the next ...

The aim of immunotherapy strategies is to leverage cells in the patient's own immune system to destroy tumor cells. Using a preclinical model, scientists from the Institut Pasteur and Inserm ...

Cancer cells can brainwash their neighbors. Like the CIA deploying secret agents to turn an enemy, tumors use a similar strategy to manipulate nearby cells. The tumors’ agents are mitochondria, the ...

A first-in-class antisense oligonucleotide — RES-010 (Resalis Therapeutics, Turin, Italy) — may complement and enhance the efficacy of antiobesity drugs such as GLP-1 receptor agonists (RAs), ...

If you're not already familiar with it, Fluor (FLR 4.87%) is a diversified construction and engineering company whose shares have sunk by around 17.5% year to date (date: Sept. 9, 2025). That decline ...